InventisBio Co Ltd
688382
Company Profile
Business description
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
Contact
No. 4, Lane 67, Li Bing Road
Room 210
Pilot Free Trade Zone
Shanghai201203
CHNT: +86 2150778527
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
182
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,553.06 | 67.42 | 0.79% |
| DAX 40 | 25,705.77 | 93.74 | 0.37% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,917.61 | 20.34 | 0.19% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |